Revolutionary Therapy Cured Three “Incurable” Autoimmune Diseases in a Patient

An incredible success story for CAR-T cell therapy.

10 Apr 2026, 13:31 by Mihai Andrei · ZME Science

Car-T cell therapy is “borrowed” from cancer treatment. Image in Creative Commons.

A 47-year-old woman in Germany had spent more than a decade battling three severe autoimmune diseases at once: autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome (APS). She had already gone through nine lines of treatment without lasting success and had reached the point of needing daily blood transfusions and permanent blood thinners.

Life was gruesome.

Then, doctors decided to try an extreme solution, a reboot of her entire immune system. They used CAR-T cell therapy, a therapy that has shown great promise in cancer treatment. The results, published recently, are being described as nothing short of a scientific landmark.

The Triple-Threat

The 47-year-old patient was living a nightmare. The AIHA was making the body produce antibodies that destroyed her red blood cells. Her immune system essentially ate her oxygen supply. Then, she had ITP, where the body wipes out platelets. Without platelets, a papercut can become a crisis. Thirdly, she had APS which does the opposite — it causes the blood to clump into dangerous, life-threatening clots.

Doctors tried everything: heavy-duty steroids, immune-suppressing drugs, even targeted antibodies. Nothing worked, her immune system was like a runaway train. When she arrived at the clinic of Dr. Fabian Müller at the University Hospital of Erlangen in Germany in 2025, she was “refractory,” a clinical word that often means “we have nothing left to try.” She required daily infusions of blood.

But there was one silver lining.

The common denominator in all three of her diseases was a rogue faction of B cells. These are like memory cells of the immune system. Usually, they remember what a virus looks like so they can pump out antibodies to kill it. In this patient, the B cells had a warped memory and mistook her own blood as the enemy. The Erlangen team realized that if they wanted to save her, they couldn’t just suppress the B cells. They had to execute them. Every single one.

Engineering the Perfect Soldier

The team turned to CAR-T cell therapy. For the last decade, this technology has gained praise as a cure for blood cancers like leukemia.

Get smarter every day...

Stay ahead with ZME Science and subscribe.

Daily Newsletter
The science you need to know, every weekday.

Weekly Newsletter
A week in science, all in one place. Sends every Sunday.
No spam, ever. Unsubscribe anytime. Review our Privacy Policy.

Thank you! One more thing...

Please check your inbox and confirm your subscription.

CAR-T cell therapy involves a high-tech game of retraining a patient’s immune cells. In this case, the doctors took out T cells, the assassins inside the immune systems. Then, in a lab, they used genetic engineering to give these T-cells a new set of instructions. They equipped the cells with a “Chimeric Antigen Receptor” (the CAR in CAR-T), which acts like a biological GPS. This GPS was programmed to lock onto a protein called CD19.

Where do you find CD19? On the surface of B cells. In essence, the T cells were given a target to hunt down the B cells, which were the source of her three diseases.

Then, once this was done, the cells were infused back into the woman’s veins. It’s a one-time treatment. The cells were alive and started scanning the patient’s tissues, killing the B cells as they went.

The results were amazing.

Within seven days, she didn’t require blood transfusions anymore. Two weeks later, she felt strong enough to walk around and do chores. Within twenty-five days, her hemoglobin levels had doubled, essentially going back to normal. The civil war inside her veins had ceased. The CAR-T cells had wiped the slate clean. They stayed in her system for months, acting as a security detail to ensure no rogue B cells returned too early.

A Clean Slate

Eventually, the CAR-T cells finished their job and faded away, allowing the patient’s body to naturally produce new B cells. In a typical autoimmune patient, you might expect the new B cells to be just as broken as the old ones. But they weren’t.

The researchers found that when her B cells returned, they were “naive.” Basically, they were unbiased, healthy cells. The CAR-T cells were so effective they forced the immune system to grow up all over again, this time correctly. It has been over a year since her treatment, and she is still in remission. She takes no medication for her autoimmune diseases.

Of course, there are caveats.

Critics and cautious scientists will rightly point out that this is a single case study. They’d be right. This is a remarkable success, but still just one patient. Case reports can reveal what is possible; they do not prove what is reliable. We still do not know how durable the remission will be, which autoimmune diseases are most likely to respond, or how the risks will look in larger, more diverse groups of patients.

CAR-T therapy is also expensive and challenging. But if it works, we can potentially save patients from decades of organ damage and side effects from chronic steroid use. We are seeing similar success stories in patients with lupus and multiple sclerosis.

Currently, we save CAR-T for the “last-ditch” effort because it is expensive and requires a grueling process of “clearing space” in the bone marrow with chemotherapy before the infusion. But if we used this “living drug” earlier, we could potentially save patients from a decade of organ damage and the side effects of chronic steroid use.

The study was published in Cell.